Related Experiment Videos
Deeply invasive candidiasis
Luis Ostrosky-Zeichner1, John H Rex, John Bennett
1Division of Infectious Diseases, University of Texas-Houston Medical School, 6431 Fannin, JFB 1.728, Houston, TX 77030, USA. Luis.Ostrosky-Zeichner@uth.tmc.edu
Abstract:
The incidence of invasive candidiasis is on the rise because of increasing numbers of immunocompromised hosts and more invasive medical technology. Recovery of Candida spp from several body sites in a critically ill or immunocompromised patient should raise the question of disseminated disease. Although identification to the species level and antifungal susceptibility testing should guide therapy, at this time amphotericin B preparations are the usual initial therapy for severe life-threatening disease. Azole therapy has an expanding body of evidence that proves it is as effective as and safer than amphotericin B therapy. Some forms of candidiasis (e.g., those with ocular, bone, or heart involvement) require a combined medical and surgical approach.
Insights
Invasive candidiasis is increasing due to immunocompromised patients and advanced medical procedures. Azole therapy is emerging as a safer and effective alternative to amphotericin B for severe infections.
Area of Science:
- Infectious Diseases
- Mycology
- Critical Care Medicine
Background:
- Invasive candidiasis incidence is rising globally.
- Increasing numbers of immunocompromised patients and invasive medical technologies contribute to this trend.
- Candida species recovery from multiple sites in critically ill patients warrants investigation for disseminated disease.
Purpose of the Study:
- To review the current understanding and management of invasive candidiasis.
- To compare the efficacy and safety of amphotericin B and azole therapies.
- To highlight the importance of species identification and antifungal susceptibility testing.
Main Methods:
- Literature review of invasive candidiasis.
- Analysis of treatment guidelines and clinical evidence.
- Comparison of therapeutic outcomes for amphotericin B and azole antifungals.
Main Results:
- Amphotericin B remains a common initial therapy for severe, life-threatening invasive candidiasis.
- Azole therapy demonstrates comparable efficacy to amphotericin B with an improved safety profile.
- Species identification and susceptibility testing are crucial for guiding appropriate antifungal selection.
Conclusions:
- Invasive candidiasis requires prompt diagnosis and tailored treatment.
- Azole antifungals represent a viable and often preferred alternative to amphotericin B.
- Multidisciplinary approaches, including surgical intervention, may be necessary for specific invasive candidiasis presentations.